AC Immune SA
corporate_fare Company Profile
AC Immune SA (NASDAQ:ACIU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACIU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ACIU spans 6-K, 20-F.
Recent high-impact activity:
- AC Immune Posts 13-Cent Quarterly Loss, Cash Runs Into 2028
- AC Immune Q3: CHF 73.9M Cash, Runway Into Q1 2028, Loss Narrowed to CHF 8.8M
- AC Immune's Parkinson's Vaccine Hits All Primary Endpoints in Phase 2 Part 1
- AC Immune's ACI-7104 Hits All Primary Endpoints in Phase 2 Parkinson's Trial
- AC Immune's NLRP3 Inhibitor Shows Brain Penetration, Advances to Phase 1b
Financial Snapshot
Short Interest & Short Volume
16.88 days to coverFINRA reported short interest of 2,947,102 shares in ACIU as of the October 30, 2026 settlement, a 9.7% decrease from the prior period — about 16.9 days to cover at its recent average daily volume. On November 20, 2026, 56.0% of ACIU volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
ACIU files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.